Prof. Dr. Simon Schäfer leads the Schäfer Lab at the Technische Universität München , focusing on engineering advanced organoid systems to study human brain development, disease modeling, and repair mechanisms. His work bridges stem cell biology, gene editing, and bioengineering to develop personalized therapies for brain disorders. Stem Cell & Organoid Technology Neurodevelopmental Mechanisms Neurodegenerative Disease Models Gene Editing & Neuroimmune Interactions Translational Neuroscience Recent research emphasizes brain organoid development, microglia phenotypes, and neurodevelopmental timing anomalies in autism. His team’s work also explores zika virus interactions with glioblastoma stem cells and neuronal plasticity in psychiatric disorders. Scientific awards and funding include support from the Deutsche Forschungsgemeinschaft (DFG), Brain & Behavior Research Foundation (BBRF), and Munich Cluster for Systems Neurology (SyNergy). Collaborations span institutions like the TUM Center for Organoid Systems. Advises 6 students (2 PhD, 1 MSc, 3 associated) Labs include Schäfer Lab, COS@TranslaTUM Contact: simon.schafer@tum.de
Katy D. Heath is a Professor of Plant Biology and Affiliate Professor in Microbiology at the University of Illinois Urbana-Champaign (UIUC). She leads the Plant Biology department and is affiliated with the Carl R. Woese Institute for Genomic Biology. Her research focuses on the evolution of mutualisms, particularly plant-microbe interactions such as legume-rhizobium symbiosis, emphasizing genetic and ecological factors influencing symbiotic stability and adaptation. She investigates how environmental pressures (e.g., global change) shape mutualistic relationships and microbial community dynamics. Education: B.S. (2000) and Ph.D. (2007) from the University of Illinois and University of Minnesota, respectively, followed by postdoctoral work at the University of Toronto (2007–2009). Research Interests: Symbiosis evolution, microbial genetics, plasmid transmission dynamics, and the impacts of agricultural practices on rhizobia populations. She studies diverse systems, including Medicago-Sinorhizobium, soybean-Bradyrhizobium, and invasive legume-rhizobium interactions. Recent publications (2020–2025) highlight studies on endophyte impacts on soybean yield, rhizobia diversity under conventional farming, and genomic analyses of symbiotic coevolution. Her work integrates molecular biology, quantitative genetics, and ecology. Grants & Collaborations: Lead PI on a $12.5M NSF Biology Integration Institute (Genomics and Eco-evolution of Multi-scale Symbiosis). Her team includes collaborations with institutions like Indiana University and the University of Chicago. Labs & Teams: Heath Lab focuses on symbiosis research, with active projects on microbiome dynamics, plasmid-host coevolution, and community outreach (e.g., Boys and Girls Club collaborations). Recent lab highlights include student graduations (e.g., Ivan Sosa Marquez, Chase) and awards like the John R. Laughnan Award in Plant Biology.
Torben Barington is a Clinical Professor at the Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, and a Consultant at the Department of Clinical Immunology, Odense University Hospital. He has held this position since August 2001 and continues to be actively involved in research, teaching, and clinical leadership. MD, University of Copenhagen, 1987 Doctoral Thesis (dr.med.), University of Copenhagen, 1996 Specialist in Clinical Immunology, 1998 His research focuses on cellular immunotherapy of cancer , particularly using CAR T-cell and CAR NK-cell technologies, primary immunodeficiencies , and the B-lymphocyte repertoire and immunoglobulin genes . His work bridges fundamental immunology with clinical applications in oncology and immunodeficiency disorders. His recent publications (2024–2025) highlight advancements in CAR T/NK-cell characterization, cytotoxicity assays, clinical translation, and tumor microenvironment interactions. These works reflect a strong trend toward translational immunology , with emphasis on personalized cancer therapy , single-cell technologies , and clinical trial development . Scientific Awards: Aage og Edith Dyssegaards Fonds æreslegat (1993) Silver Medal, University of Copenhagen (1981) He has supervised over 30 thesis students and currently mentors several graduate students in CAR-based cancer immunotherapies. He serves as an examiner for PhD defenses at both the University of Southern Denmark and the University of Copenhagen. He is also actively involved in national scientific leadership, including as Chairman of the Scientific Committee of the Danish Blood Donor Organization since 2011 and as a member of the Advisory Board for Clinical Immunology in the Region of Southern Denmark since 2007. His research is conducted in collaboration with multidisciplinary teams focusing on cellular immunotherapy , clinical immunology , and translational hematology , often in partnership with Odense University Hospital and national blood and immunology networks.
Ovijit Chaudhuri is an Associate Professor of Mechanical Engineering at Stanford University, with a courtesy appointment in Bioengineering. He leads research at the interface of mechanics and biology, focusing on how cellular and extracellular mechanical properties influence biological processes like cancer progression and tissue formation. His work employs advanced tools such as atomic force microscopy and 3D cell culture systems. Education: Ph.D., University of California, Berkeley/San Francisco (Bioengineering, 2009) B.S., University of California, Berkeley (Engineering Physics, 2003) Postdoctoral Fellow, Harvard University (Biomaterials, 2013) Research Interests: His lab explores molecular mechanisms behind cellular mechanics, extracellular matrix dynamics, and how mechanical cues regulate cell behavior. Key areas include cancer metastasis, mechanotransduction, and engineered biomaterials for 3D cell culture. Publications Trends: Recent work emphasizes viscoelastic hydrogels, matrix mechanics in cancer progression, and mechanistic insights into cell migration. Over 50 publications since 2015 highlight interdisciplinary approaches in biomaterials and mechanobiology. Awards: Not explicitly listed in provided materials. Advising & Labs: No specific advisee names listed, but his lab focuses on collaborative projects in mechano-biology. Active in developing biomaterial systems for drug discovery and tissue engineering applications. Labs/Teams: Leads the Chaudhuri Lab at Stanford, which integrates engineering principles with biological systems to address complex disease mechanisms and therapeutic strategies.
George Perry is a Professor of Anthropology at Pennsylvania State University, with research intersections in Biology, Evolutionary Medicine, and Genomics. He is affiliated with the Huck Institutes' Center for Infectious Disease Dynamics, Ecology, Molecular Cellular and Integrative Biosciences, and Bioinformatics and Genomics programs. Perry directs the Anthropological Genomics Lab , focusing on paleogenomics and evolutionary adaptation. Research areas: anthropological genomics, parasite evolution, human body size transitions, and evolutionary medicine Key collaborations: international teams in Madagascar, Europe, and Africa Leadership: Bioinformatics and Genomics Chair (2019–2023) His 2025–2022 publications span evolutionary responses to invasive species, human migration health impacts, chemosensory gene adaptation, and primate genomic diversity. Notable methodological contributions include ancient DNA recovery and comparative paleogenomics. Perry advises graduate students like Vanessa Garcia and Annette Mercedes, with grants including NIH support for Cuban health disparity studies. Scientific leadership includes tenure-line promotions (2023) and NASA Space Grant collaborations.
Dana Pe'er is a Professor and Chair of the Computational and Systems Biology Program at the Sloan Kettering Institute (SKI) of Memorial Sloan Kettering Cancer Center. She is also an Investigator of the Howard Hughes Medical Institute and holds the Alan and Sandra Gerry Endowed Chair. Dr. Pe'er leads an interdisciplinary research group that combines advanced genomics approaches with machine learning to address fundamental questions in biomedical science, with particular focus on cancer biology, developmental biology, and immunology. Dr. Pe'er earned her PhD from Hebrew University in Jerusalem, Israel. Her academic journey includes a postdoctoral fellowship with George Church at Harvard Medical School. Before joining Memorial Sloan Kettering Cancer Center in 2016, she held faculty positions at Columbia University. Dr. Pe'er's research focuses on understanding cellular plasticity, the consequences of intra-tumor heterogeneity, cancer evolution and metastasis, and the mechanisms by which regulatory circuits go awry in disease. Her lab combines single-cell and spatial profiling technologies with machine learning approaches to investigate gene regulation, cellular plasticity, and cell-cell communication in the contexts of cancer, immunity, and development. They are particularly interested in how organisms develop from a single cell to generate diverse cell types, how epigenetic control rewires during development, and how cells communicate to execute multicellular responses. Analysis of Dr. Pe'er's recent publications reveals a strong focus on developing computational methods for single-cell and spatial genomics data analysis. Her work spans cancer types including pancreatic, prostate, colorectal, and breast cancer, with emphasis on tumor heterogeneity, metastasis mechanisms, and cellular plasticity. A significant portion of her research involves creating novel algorithms and tools like CellRank, REUNION, and SEACells that enable researchers to extract meaningful biological insights from complex genomic datasets. 2023 Class of 2023 Inductee - American Academy of Cancer Research (AACR) Academy 2023 Innovator Award - International Society for Computational Biology (ISCB) 2021 Fellow - International Society for Computational Biology (ISCB) Howard Hughes Medical Institute Investigator (2021) 2019 Ernst W. Bertner Memorial Award - University of Texas MD Anderson Cancer Center 2016 Lenfest Distinguished Faculty Award - Columbia University 2014 Director's Pioneer Award - National Institutes of Health 2014 Overton Prize - International Society for Computational Biology (ISCB) Dr. Pe'er is known for her dedicated mentorship approach, describing herself as "a mama bear" who cares deeply about her trainees while expecting independence, innovation, and hard work. She mentors numerous PhD students and postdocs in her lab. Her HHMI Investigator award provides approximately $9 million over seven years, enabling ambitious research directions. She also collaborates extensively with the Single-cell Analytics and Innovation Lab (SAIL) at MSK to generate new data from emerging technologies, working closely with wet-lab collaborators at MSK and beyond to apply computational methods to cutting-edge datasets across multiple disease areas. The Pe'er Lab is an interdisciplinary group of computational biologists with diverse backgrounds ranging from pure mathematics to clinical medicine. They work closely with wet-lab collaborators to apply their computational methods to cutting-edge datasets across cancer, immunology, and developmental biology. The lab is described as open, supportive, collaborative, and fun, with access to world-class facilities at the Sloan Kettering Institute. Dr. Pe'er's work continues to push the boundaries of computational biology and cancer research, with the ultimate goal of developing more effective, personalized therapies for cancer patients.
Ping He is a Professor in the Department of Molecular, Cellular, and Developmental Biology (MCDB) at the University of Michigan in Ann Arbor. His research focuses on plant immunity mechanisms, particularly using Arabidopsis as a model system to study pathogen defense activation, signaling pathways, and the interplay between immunity and environmental stress responses. He also leads the Molecular, Plant-Microbe Interaction Laboratory, applying interdisciplinary approaches (genetics, biochemistry, cellular biology) to enhance crop resilience through foundational plant science discoveries. His work bridges plant biology and computational biology, with recent contributions to AI-driven medical imaging applications such as bladder cancer treatment response assessment, lung cancer early detection, and breast tomosynthesis denoising. These efforts emphasize integrating machine learning into clinical workflows and establishing best practices for AI in healthcare. Research Highlights: Plant immunity signaling and environmental stress crosstalk Radiomics and deep learning for cancer diagnosis/prognosis AI model validation and multi-institutional clinical trials Medical imaging artifact correction (e.g., motion blur, noise) Publications emphasize AI applications in oncology imaging, radiologist decision support systems, and multimodal data fusion. He has contributed to AAPM task group guidelines for AI in computer-aided diagnosis and advocates for rigorous quality assurance frameworks in medical AI deployment.
Professor Hanadi Sleiman is a renowned academic in the Department of Chemistry at McGill University, specializing in DNA-based nanomaterials and their applications in drug delivery and supramolecular chemistry. She holds leadership roles, including Director of the NSERC CREATE training program in Nucleic Acids and President of the International DNA Nanotechnology Society (ISNSCE). Her research focuses on engineering DNA nanostructures for targeted therapies, such as cancer treatments, and advancing materials chemistry through DNA-functionalized systems. Education: Ph.D. in Chemistry, Stanford University (1990) Postdoctoral Fellow, University of Louis Pasteur (1993) Research Interests: Professor Sleiman’s work combines synthetic chemistry with DNA self-assembly to create programmable materials. Her lab designs DNA cages for drug encapsulation, explores DNA-minimal approaches to scalable materials, and integrates DNA with nanoparticles, polymers, and metals for biomedical applications. Key areas include cancer therapy, biosensors, and enzyme mimics. Awards & Honors: Fellow of the Royal Society of Canada (2017) Killam Research Fellowship (2018) R. U. Lemieux Award in Organic Chemistry (2018) William Dawson Scholar Award (2004–2012) Grants & Collaborations: She directs the NSERC CREATE program and collaborates with institutions like the Quebec Centre for Advanced Materials (QCAM) and the McGill Centre for Structural Biology (CRBS). Her training initiatives emphasize nucleic acid therapeutics and diagnostics. Labs & Teams: Her Sleiman Group at McGill develops innovative DNA architectures in the Otto Maass laboratory, with a focus on translational research for clinical applications.
Jianhua Xing is an Associate Professor in the Department of Physics & Astronomy at the University of Pittsburgh , affiliated with the Dietrich School of Arts and Sciences . His research focuses on applying physics-based approaches to study biological systems, particularly cell phenotypic transitions (CPTs) and their underlying dynamics. He integrates quantitative single-cell measurements with computational and theoretical analyses to understand how cells transition between stable states. Key research areas include: Nonequilibrium systems and rate theories for biological transitions Single-cell trajectory analysis and live-cell imaging Epithelial-mesenchymal transition (EMT) dynamics Gene regulatory networks and stochastic processes Biological applications of dynamical systems theory Recent work highlights the coupling between EMT and cell cycle arrest, leveraging machine learning frameworks (e.g., LivecellX ) for high-resolution imaging analysis. His lab also explores chromosomal dynamics and mechanotransduction in stem cell aging. Publications emphasize data-driven modeling and theoretical insights, with contributions to frameworks like GraphVelo and Graph-Dynamo for inferring cellular state transitions. Collaborative efforts bridge physics, biology, and computational science to address fundamental biological questions. No awards or grants are explicitly listed in the provided texts. His research group focuses on advancing systems biology through interdisciplinary methods, with a lab dedicated to quantitative analysis of cellular processes.
Amy Catherine Rowat is a full Professor in the Department of Integrative Biology and Physiology at UCLA's College of Letters and Science. She directs an interdisciplinary research program that integrates mechanobiology, microfluidics, cancer biophysics and food engineering to understand how physical forces shape cell behavior and to develop sustainable biotechnologies. Education & Affiliations: Professor, Department of Integrative Biology and Physiology, UCLA Member, UCLA College of Letters and Science Research Interests: Rowat's group deciphers how mechanical properties of cells and their nuclei influence disease progression and therapeutic response. Using high-throughput microfluidic deformability cytometry, her team discovered that cancer cells become stiffer and more invasive upon β-adrenergic signaling, linking stress hormones to metastatic potential. Parallel efforts focus on nuclear envelope mechanics, showing that histone H1.0 and transient nuclear deformation modulate chromatin structure and cell reprogramming. Beyond biomedicine, Rowat pioneers biophysical approaches for sustainable food production. She engineers edible scaffolds and emulsion-templated microcarriers to culture meat at scale, demonstrating spontaneous fusion of adipogenic and myogenic microtissues into marbled steak-like constructs. Recent Article Trends (2020-2025): Her latest publications reveal a cohesive trajectory: coupling mechanobiology to epigenetic regulation (viscoelastic matrix enhances chromatin remodeling), advancing single-cell mechanical phenotyping (optomagnetic arrays, high-throughput screens), translating findings to cancer therapy (β-blockers to sensitize chemotherapy) and expanding engineered foods (scalable cultured-meat bioprocessing). Funding & Awards: NIH R21 CA245667 (PI) – Repurposing beta-blockers to improve chemotherapy response (2021-2023) Laboratory & Teams: Rowat leads an active research laboratory at UCLA that trains graduate students and postdocs at the intersection of physics, engineering and biology. The lab maintains collaborations across UCLA Engineering, Jonsson Comprehensive Cancer Center, and external partners in food science and biotechnology companies.
Brinton Seashore-Ludlow is an Associate Professor at the Department of Oncology-Pathology, Karolinska Institute (KI), where he serves as team leader in Olli Kallioniemi's research group and group leader of the biology team at Chemical Biology Consortium Sweden (CBCS), SciLifeLab's national infrastructure. PhD in Biochemistry, KTH Royal Institute of Technology (2012) MSc in Chemical Biology, California Institute of Technology (2007) BA in Biochemistry, Macalester College (2001) His research bridges precision medicine and cancer biology through: Developing ex vivo patient-derived models for drug response prediction Molecular determinants of therapeutic efficacy Integration of high-content imaging with translational studies Focus on ovarian, breast, and pediatric cancers AI-driven analysis of drug sensitivity data Recent articles demonstrate: 3D tumor spheroid platforms for drug testing Epigenetic regulators in neuroblastoma Microfluidics for high-throughput assays Cancer-stroma interactions in treatment resistance Clinical validation of precision diagnostics He co-organizes the Overview Course in Cancer Drug Discovery at KI and leads projects funded by the Swedish Childhood Cancer Foundation.
Dr. Parth Chansoria is a Lecturer at the Department of Health Sciences and Technology at ETH Zürich, where he leads biofabrication research within the Tissue Engineering and Biofabrication (TEB) group. His work focuses on structured light technology for regenerative medicine applications, including in vivo bioprinting and microgravity-based tissue engineering. He holds Ambizione and Spark grants from the Swiss National Science Foundation and has pioneered innovations in light-guided biofabrication, collagen-based resins, and anisotropic tissue design. Research domains include: Filamented light biofabrication for aligned tissues Minimally invasive light-based in vivo bioprinting Musculoskeletal tissue engineering in microgravity Isotonic collagen-based photocrosslinkable resins He has secured over 6 patents and received prestigious awards including the ISBF Early Career Investigator Award (2022), Marie Curie Actions Fellowship (2021), and SME 30 Under 30 recognition (2021). His interdisciplinary research bridges bioengineering, materials science, and clinical applications. Key collaborations include projects at UNC Chapel Hill (USA) and NC State (USA), where he developed biomimetic patches for dynamic organ pathologies and ultrasound-assisted cell patterning. His lab explores novel bioinks, hybrid fabrication techniques, and translational applications in regenerative medicine.
Steven R. Caliari is an Associate Professor in the Department of Chemical Engineering with a secondary appointment in Biomedical Engineering at the University of Virginia’s School of Engineering and Applied Science. He serves as the ChE Graduate Program Director and is a SEAS Copenhaver Fellow (2023). His research focuses on designing biomaterials to study cell-microenvironment interactions, addressing challenges in disease and tissue engineering. He holds a B.S. (2007, University of Florida), M.S. (2010), and Ph.D. (2013) in Chemical Engineering from the University of Illinois, followed by an NIH postdoctoral fellowship at the University of Pennsylvania. His research interests include biomaterials, mechanobiology, musculoskeletal tissue engineering, and advanced manufacturing for biological applications. His lab has pioneered viscoelastic hydrogel platforms and conductive collagen scaffolds, supported by NIH, NSF, DoD, and industry grants. Notable awards include the NSF CAREER Award (2021) and NIH MIRA (2020). Grants: NIH (NIGMS), NSF CAREER, V Foundation, UVA-Coulter Partnership Courses: Tissue Engineering (BME/CHE 4417), Transport Processes I (CHE 3321) Labs: Caliari Lab focuses on biomaterial design and mechanobiological studies His work bridges fundamental science and translational applications, emphasizing dynamic material systems for regenerative medicine and disease modeling.
Sean J. Morrison is the founding Director of the Children’s Medical Center Research Institute at UT Southwestern (CRI) and a Howard Hughes Medical Institute Investigator. He holds the Mary McDermott Cook Chair in Pediatric Genetics and the Kathryne and Gene Bishop Distinguished Chair in Pediatric Research. Dr. Morrison earned his B.Sc. in Biology and Chemistry from Dalhousie University (1991), a Ph.D. in Immunology from Stanford University (1996), and completed a postdoctoral fellowship in Neurobiology at Caltech (1999). Education: B.Sc. - Dalhousie University (Biology & Chemistry, 1991) Ph.D. - Stanford University (Immunology, 1996) Postdoctoral Fellowship - Caltech (Neurobiology, 1999) Research Interests: Dr. Morrison’s laboratory investigates the mechanisms that maintain adult tissues and how cancer cells exploit these processes to form tumors. His team compares stem cell and cancer cell replication mechanisms to develop novel regenerative medicine and anticancer therapies. Key areas include: Stem cell self-renewal and aging Metabolic regulation of hematopoietic stem cells Leptin Receptor+ stromal cell function Cancer progression and metastasis Proteostasis and niche biology Mechanotransduction in stem cell niches Publications reveal trends in stem cell metabolism, tumor heterogeneity, and niche dynamics across Science , Nature , and Cell . His work on retrotransposons in stem cell activation (2024) and β-adrenergic receptor inhibition in hematopoietic regeneration (2024) highlights emerging therapeutic targets. Awards & Recognitions: Dr. Morrison is an elected member of the U.S. National Academy of Medicine (2018), National Academy of Sciences (2020), and EMBO (2023). He received the Presidential Early Career Award (2003), MERIT Award from NIA (2009), and UT Southwestern’s Excellence in Postdoctoral Mentoring Award (2020). Mentorship & Leadership: Dozens of graduate students and postdoctoral fellows from his lab have secured academic leadership roles or industry positions. He served as President of the International Society for Stem Cell Research (2015–2016) and actively engages in public policy debates about stem cell research, including Michigan’s constitutional protections for regenerative medicine.
Ash A. Alizadeh is the Moghadam Family Professor of Medicine, Oncology, and Hematology (by courtesy) at Stanford University, where he serves as leader of the Cancer Genomics Program at Stanford Cancer Institute. He holds multiple academic appointments including Professor in Medicine - Oncology, and membership in Bio-X, the Institute for Stem Cell Biology and Regenerative Medicine, and the Maternal & Child Health Research Institute (MCHRI). Dr. Alizadeh received his BS in Biochemistry from UCLA (1994), MD from Stanford Medical School, and PhD in Biophysics from Stanford. He completed additional training at the National Cancer Institute (NCI), the National Institutes of Health (NIH), and the Howard Hughes Medical Institute (HHMI). His primary research focuses on developing and applying genome technologies and computing (machine learning & data science) to problems in human disease, with special emphasis on cancer detection, classification, monitoring, and tumor immunology. His laboratory pioneers noninvasive cancer genomic techniques including CAPP-Seq, PhasED-Seq, and EPIC-Seq for "liquid biopsies" that analyze circulating nucleic acids for early cancer detection and monitoring therapeutic response. Using machine learning approaches, his group studies how cellular compositional variation impacts cancer behavior and therapeutic response, including anti-tumor immunity. His work spans molecular, cellular, organism and population levels of tumor behavior analysis. Dr. Alizadeh has received numerous prestigious awards including the Scholar Award from the American Society of Hematology (ASH), the Leukemia & Lymphoma Society (LLS), the V-Foundation, as well as awards from the American Red Cross, Damon Runyon Cancer Research Foundation, and Doris Duke Charitable Research Foundation. He is an elected member of the American Society for Clinical Investigation (ASCI) and serves on the Scientific Advisory Board of the Lymphoma Research Foundation (LRF). As an educator and mentor, Dr. Alizadeh advises numerous doctoral students, postdoctoral fellows, and medical scholars. He teaches in the Department of Medicine and Immunology and serves on various admissions panels at Stanford. His laboratory, the Alizadeh Lab, is a hub for interdisciplinary cancer genomics research that combines computational biology, molecular genetics, and clinical oncology to develop novel cancer diagnostics and therapeutics.
